• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

成骨不全患者吡啶啉交联形成受损。

Impaired pyridinoline cross-link formation in patients with osteogenesis imperfecta.

作者信息

Hasegawa Kosei, Kataoka Kyoko, Inoue Masaru, Seino Yoshiki, Morishima Tsuneo, Tanaka Hiroyuki

机构信息

Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikatacho, Okayama 700-8558, Japan.

出版信息

J Bone Miner Metab. 2008;26(4):394-9. doi: 10.1007/s00774-007-0827-z. Epub 2008 Jul 4.

DOI:10.1007/s00774-007-0827-z
PMID:18600407
Abstract

Patients with osteogenesis imperfecta (OI) show various degrees of bone fragility. Nevertheless, details of the mechanisms causing bone fragility remain unclear. We hypothesized that differences in pyridinoline cross-link formation at the N-and C-termini in type I collagen molecules partly contribute to bone fragility of OI. To verify this hypothesis, urinary N and C terminal telopeptides of type I collagen (uNTx and ubetaCTx, respectively) and urinary hydroxyproline (uHyp) were measured using second morning void urine samples obtained from OI patients and healthy control children. Ratios of uNTx and ubetaTx to uHyp (uNTx/uHyp and ubetaCTx/uHyp, respectively) of OI patients and healthy normal control children were analyzed. Ratios of uNTx to ubetaCTx (uNTx/ubetaCTx) were also analyzed. In OI patients, uNTx and ubetaCTx were lower than in healthy control children. Also, uNTx/uHyp and ubetaCTx/uHyp were significantly lower than in healthy children. Among OI patients, uNTx/uHyp and uNTx/ubetaCTx of type III OI were significantly lower than of either type I or type IV OI. These results show that pyridinoline cross-link formation is lower than in healthy control children and that pyridinoline cross-link formation at the N-and C-termini in type I collagen molecules might be differently disrupted in OI patients according to the severity of OI.

摘要

成骨不全症(OI)患者表现出不同程度的骨脆性。然而,导致骨脆性的机制细节仍不清楚。我们推测I型胶原分子N端和C端吡啶啉交联形成的差异部分导致了OI的骨脆性。为了验证这一假设,我们使用从OI患者和健康对照儿童采集的晨尿样本测量了I型胶原的尿N端和C端末端肽(分别为uNTx和uβCTx)以及尿羟脯氨酸(uHyp)。分析了OI患者和健康正常对照儿童的uNTx和uβTx与uHyp的比值(分别为uNTx/uHyp和uβCTx/uHyp)。还分析了uNTx与uβCTx的比值(uNTx/uβCTx)。在OI患者中,uNTx和uβCTx低于健康对照儿童。此外,uNTx/uHyp和uβCTx/uHyp显著低于健康儿童。在OI患者中,III型OI的uNTx/uHyp和uNTx/uβCTx显著低于I型或IV型OI。这些结果表明,吡啶啉交联形成低于健康对照儿童,并且I型胶原分子N端和C端的吡啶啉交联形成在OI患者中可能根据OI的严重程度而受到不同程度的破坏。

相似文献

1
Impaired pyridinoline cross-link formation in patients with osteogenesis imperfecta.成骨不全患者吡啶啉交联形成受损。
J Bone Miner Metab. 2008;26(4):394-9. doi: 10.1007/s00774-007-0827-z. Epub 2008 Jul 4.
2
Urinary Cross-linked N-terminal Telopeptide of Type I Collagen Levels of Infants with Osteogenesis Imperfecta and Healthy Infants.成骨不全婴儿与健康婴儿的尿I型胶原交联N末端肽水平
Acta Med Okayama. 2016 Dec;70(6):435-439. doi: 10.18926/AMO/54805.
3
Evidence for a Role for Nanoporosity and Pyridinoline Content in Human Mild Osteogenesis Imperfecta.纳米孔隙率和吡啶啉含量在人类轻度成骨不全中作用的证据。
J Bone Miner Res. 2016 May;31(5):1050-9. doi: 10.1002/jbmr.2780. Epub 2016 Feb 11.
4
Pyridinium cross-links in bone of patients with osteogenesis imperfecta: evidence of a normal intrafibrillar collagen packing.成骨不全症患者骨骼中的吡啶交联:原纤维内胶原蛋白正常堆积的证据。
J Bone Miner Res. 2000 Jul;15(7):1330-6. doi: 10.1359/jbmr.2000.15.7.1330.
5
Collagen crosslinks and mineral crystallinity in bone of patients with osteogenesis imperfecta.成骨不全症患者骨骼中的胶原蛋白交联和矿物质结晶度。
J Bone Miner Res. 1993 Feb;8(2):133-7. doi: 10.1002/jbmr.5650080203.
6
Bone turnover markers in patients with osteogenesis imperfecta.成骨不全症患者的骨转换标志物
Bone. 2004 Jun;34(6):1013-6. doi: 10.1016/j.bone.2004.02.023.
7
Impact of alendronate on quality of life in children with osteogenesis imperfecta.阿仑膦酸盐对成骨不全患儿生活质量的影响。
J Pediatr Orthop. 2005 Nov-Dec;25(6):786-91. doi: 10.1097/01.bpo.0000176162.78980.ed.
8
Health-related quality of life in children with osteogenesis imperfecta: a large-sample study.成骨不全症患儿的健康相关生活质量:一项大样本研究。
Osteoporos Int. 2019 Feb;30(2):461-468. doi: 10.1007/s00198-018-4801-5. Epub 2018 Dec 19.
9
Bone resorption assessed by immunoassay of urinary cross-linked collagen peptides in patients with osteogenesis imperfecta.通过免疫测定成骨不全患者尿中交联胶原肽评估骨吸收。
J Bone Miner Res. 1994 Jul;9(7):993-7. doi: 10.1002/jbmr.5650090706.
10
Dominantly inherited osteogenesis imperfecta in man: an examination of collagen biosynthesis.人类显性遗传性成骨不全症:胶原蛋白生物合成的研究。
Pediatr Res. 1975 Feb;9(2):83-8. doi: 10.1203/00006450-197502000-00005.

引用本文的文献

1
Bone Quality and Mineralization and Effects of Treatment in Osteogenesis Imperfecta.骨质量和矿化及成骨不全症治疗的影响。
Calcif Tissue Int. 2024 Dec;115(6):777-804. doi: 10.1007/s00223-024-01263-8. Epub 2024 Sep 4.
2
Na+/H+ exchanger regulatory factor 1 (NHERF1) directly regulates osteogenesis.钠氢交换体调节因子 1(NHERF1)直接调节成骨作用。
J Biol Chem. 2012 Dec 21;287(52):43312-21. doi: 10.1074/jbc.M112.422766. Epub 2012 Oct 29.

本文引用的文献

1
Collagen overglycosylation: a biochemical feature that may contribute to bone quality.胶原蛋白过度糖基化:一种可能影响骨质量的生化特征。
Biochem Biophys Res Commun. 2005 Apr 29;330(1):1-4. doi: 10.1016/j.bbrc.2005.02.050.
2
Guidelines for the use of biochemical markers of bone turnover in osteoporosis (2004).骨质疏松症中骨转换生化标志物的应用指南(2004年)
J Bone Miner Metab. 2005;23(2):97-104. doi: 10.1007/s00774-004-0547-6.
3
Phenotypic and molecular characterization of Bruck syndrome (osteogenesis imperfecta with contractures of the large joints) caused by a recessive mutation in PLOD2.
由PLOD2隐性突变引起的布鲁克综合征(伴有大关节挛缩的成骨不全症)的表型和分子特征
Am J Med Genet A. 2004 Dec 1;131(2):115-20. doi: 10.1002/ajmg.a.30231.
4
Bone turnover markers in patients with osteogenesis imperfecta.成骨不全症患者的骨转换标志物
Bone. 2004 Jun;34(6):1013-6. doi: 10.1016/j.bone.2004.02.023.
5
The interaction between Sillence type and BMD in osteogenesis imperfecta.
Calcif Tissue Int. 2003 Nov;73(5):441-5. doi: 10.1007/s00223-002-2101-7. Epub 2003 Sep 10.
6
Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease.VII型成骨不全症:一种常染色体隐性遗传性脆性骨病。
Bone. 2002 Jul;31(1):12-8. doi: 10.1016/s8756-3282(02)00790-1.
7
Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect.VI型成骨不全症:一种伴有矿化缺陷的脆性骨病。
J Bone Miner Res. 2002 Jan;17(1):30-8. doi: 10.1359/jbmr.2002.17.1.30.
8
Thirty-three novel COL1A1 and COL1A2 mutations in patients with osteogenesis imperfecta types I-IV.I-IV型成骨不全患者中的33种新的COL1A1和COL1A2突变
Hum Mutat. 2001 May;17(5):434. doi: 10.1002/humu.1124.
9
Type V osteogenesis imperfecta: a new form of brittle bone disease.V型成骨不全症:一种新型脆性骨病。
J Bone Miner Res. 2000 Sep;15(9):1650-8. doi: 10.1359/jbmr.2000.15.9.1650.
10
Pyridinium cross-links in bone of patients with osteogenesis imperfecta: evidence of a normal intrafibrillar collagen packing.成骨不全症患者骨骼中的吡啶交联:原纤维内胶原蛋白正常堆积的证据。
J Bone Miner Res. 2000 Jul;15(7):1330-6. doi: 10.1359/jbmr.2000.15.7.1330.